MX2009012126A - 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7. - Google Patents

2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7.

Info

Publication number
MX2009012126A
MX2009012126A MX2009012126A MX2009012126A MX2009012126A MX 2009012126 A MX2009012126 A MX 2009012126A MX 2009012126 A MX2009012126 A MX 2009012126A MX 2009012126 A MX2009012126 A MX 2009012126A MX 2009012126 A MX2009012126 A MX 2009012126A
Authority
MX
Mexico
Prior art keywords
ylalkyl
piperazin
pyrazol
pyridines
phenyl
Prior art date
Application number
MX2009012126A
Other languages
English (en)
Inventor
Sandra Ann Filla
Sarah Lynne Hellman
Anne Marie Camp
Michael Philip Mazanetz
Patrick Gianpietro Spinazze
John Mehnert Schaus
Valentina O Badescu
Barry Peter Clark
Peter Thaddeus Gallagher
Marta Maria Pineiro-Nunez
Maria Anne Whatton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009012126A publication Critical patent/MX2009012126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos antagonistas selectivos del receptor 5-HT7 de Fórmula I, y su uso en el tratamiento de migraña, dolor persistente y ansiedad: en donde A y B son cada uno independientemente -C(H)= o -N=, siempre que al menos uno de A y B es -N=, n es 1-3, m es 0-3, y R1-4 son como se definen en la presente. (ver fórmula (I)).
MX2009012126A 2007-05-11 2008-05-07 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7. MX2009012126A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91743107P 2007-05-11 2007-05-11
US97420907P 2007-09-21 2007-09-21
PCT/US2008/062834 WO2008141020A1 (en) 2007-05-11 2008-05-07 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009012126A true MX2009012126A (es) 2009-11-23

Family

ID=39629131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012126A MX2009012126A (es) 2007-05-11 2008-05-07 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7.

Country Status (17)

Country Link
US (1) US8202873B2 (es)
EP (1) EP2155717B1 (es)
JP (1) JP5210375B2 (es)
KR (1) KR101119294B1 (es)
CN (1) CN101861312B (es)
AU (1) AU2008251584B2 (es)
BR (1) BRPI0811446A2 (es)
CA (1) CA2684563C (es)
CY (1) CY1113457T1 (es)
DK (1) DK2155717T3 (es)
EA (1) EA016529B1 (es)
ES (1) ES2395872T3 (es)
HR (1) HRP20120919T1 (es)
MX (1) MX2009012126A (es)
PL (1) PL2155717T3 (es)
PT (1) PT2155717E (es)
WO (1) WO2008141020A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410277B2 (en) 2007-12-26 2013-04-02 Eisai R&D Managment Co., Ltd. Method for manufacturing heterocycle substituted pyridine derivatives
BR112012008128B8 (pt) * 2009-07-31 2019-07-16 Syngenta Participations Ag processos para a preparação de um composto da fórmula | e processo para a alquilação regiosseletiva de um composto da fórmula ||
US20130005710A1 (en) 2009-11-18 2013-01-03 Tetsuya Tsukamoto Aminopyridine derivative
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2012019950A1 (en) * 2010-08-10 2012-02-16 Syngenta Participations Ag Process for the preparation of 3-haloalkylpyrazoles
MY179509A (en) * 2013-12-20 2020-11-09 Esteve Pharmaceuticals Sa Piperazine derivatives having multimodal activity against pain
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CN104592199A (zh) * 2015-01-22 2015-05-06 杭州利巴医药科技有限公司 一种取代的1-(2-吡啶基)-吡唑-4-基乙酸及其衍生物和制备方法
CN104945325B (zh) * 2015-06-19 2017-04-05 浙江永太科技股份有限公司 一种吡唑甲酸衍生物的制备方法
SG11201906922TA (en) 2017-02-17 2019-09-27 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
CA3094711A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
TWI834708B (zh) 2018-08-17 2024-03-11 美商文涵治療有限公司 Ag10之調配物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
EP1676844A1 (en) * 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
BRPI0406704A (pt) * 2003-01-31 2005-12-20 Pfizer Prod Inc Antagonistas de 5ht~7~ e agonistas inversos
US20050080076A1 (en) * 2003-10-08 2005-04-14 Xanodyne Pharmacal, Inc. N-desmethyl levomepromazine

Also Published As

Publication number Publication date
PL2155717T3 (pl) 2013-03-29
BRPI0811446A2 (pt) 2014-10-29
EA200971052A1 (ru) 2010-04-30
AU2008251584A1 (en) 2008-11-20
EP2155717A1 (en) 2010-02-24
US20100120785A1 (en) 2010-05-13
CA2684563C (en) 2013-08-13
EA016529B1 (ru) 2012-05-30
US8202873B2 (en) 2012-06-19
JP5210375B2 (ja) 2013-06-12
KR20090127436A (ko) 2009-12-11
AU2008251584B2 (en) 2013-04-11
CN101861312B (zh) 2014-09-03
ES2395872T3 (es) 2013-02-15
WO2008141020A1 (en) 2008-11-20
DK2155717T3 (da) 2012-11-19
PT2155717E (pt) 2012-12-21
JP2010526819A (ja) 2010-08-05
KR101119294B1 (ko) 2012-04-12
CA2684563A1 (en) 2008-11-20
EP2155717B1 (en) 2012-10-24
CY1113457T1 (el) 2016-06-22
HRP20120919T1 (hr) 2012-12-31
CN101861312A (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
MX2009012126A (es) 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7.
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CY1112969T1 (el) Ανταγωνιστες πιριδυλ πιπεριδινης του υποδοχεα ορεξινης
MX2013011054A (es) Antagonistas de trpvi.
WO2008139235A8 (en) Novel piperazine salts as d3/d2 antagonists
IN2014CN00408A (es)
WO2014091298A3 (en) Nitrogen containing morphinan derivatives and the use thereof
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
DOP2005000038A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5"
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
UA96764C2 (ru) Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl
MX2007003545A (es) Composiciones y metodos para tratar trastornos cognitivos.
PL2201002T3 (pl) Antagoniści receptora 5-HT7
PE20090629A1 (es) Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7
NZ603859A (en) Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
MY148488A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE400568T1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
AR077481A1 (es) Derivados de imidazol
TW200602041A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration